AU2526188A - Creación de Inventos y Patentes con Inteligencia Artificial

AU2526188A – Liposomal nucleoside analogues for treating aids
– Google Patents

AU2526188A – Liposomal nucleoside analogues for treating aids
– Google Patents
Liposomal nucleoside analogues for treating aids

Info

Publication number
AU2526188A

AU2526188A
AU25261/88A
AU2526188A
AU2526188A
AU 2526188 A
AU2526188 A
AU 2526188A
AU 25261/88 A
AU25261/88 A
AU 25261/88A
AU 2526188 A
AU2526188 A
AU 2526188A
AU 2526188 A
AU2526188 A
AU 2526188A
Authority
AU
Australia
Prior art keywords
nucleoside analogue
liposome
phosphorylated
composition according
phosphorylated nucleoside
Prior art date
1987-09-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Application number
AU25261/88A
Inventor
Karl Y. Hostetler
Douglas D. Richman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of California

Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1987-09-22
Filing date
1988-09-19
Publication date
1989-04-18

1988-09-19
Application filed by University of California
filed
Critical
University of California

1989-04-18
Publication of AU2526188A
publication
Critical
patent/AU2526188A/en

Status
Abandoned
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K31/00—Medicinal preparations containing organic active ingredients

A61K31/70—Carbohydrates; Sugars; Derivatives thereof

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K9/00—Medicinal preparations characterised by special physical form

A61K9/10—Dispersions; Emulsions

A61K9/127—Liposomes

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P31/12—Antivirals

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P31/12—Antivirals

A61P31/14—Antivirals for RNA viruses

A61P31/18—Antivirals for RNA viruses for HIV

Description

LIPOSOMAL NUCLEOSIDE ANALOGUES FOR TREATING AIDS
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates generally to the treatment of viral infections with nucleoside analogues. More particularly, the present invention relates to the encapsulation of modified antiviral nucleoside analogues in liposomes to enhance the effectiveness of the analogues when administered to mammals.
This invention was made with Government support under Grant No. : GM-24979 from the National Institutes of Health to the University of California and the
Veterans Administration. The Government has certain rights in this invention.
Description of Related Art The publications and other reference materials referred to herein to describe the background of the invention and to provide additional detail regarding its practice are hereby incorporated by reference. For convenience, the reference materials are numerically referenced and grouped in the bibliography appended at the end of this specification.
There has been a great deal of interest in recent years in the use of nucleoside analogues to treat viral infections. The antiviral nucleoside analogues are designed to inhibit viral functions by preventing the synthesis of new DNA by viral reverse transcriptase during viral replication. Nucleosides are the precursors of DNA or RNA. A nucleoside consists of a pyrimidine or purine base which is linked to a five-carbon sugar.
During DNA synthesis, free nucleoside triphosphates

(nucleosides with three phosphate groups attached) react with the end of a growing DNA chain. The reaction involves the linking of the phosphate group at the 5′ position on the incoming nucleoside triphosphate with the hydroxyl group at the 3′ position of the sugar ring on the end of the forming DNA chain. The other two phosphate groups are freed during the reaction thereby resulting in the addition of a nucleotide to the DNA chain. Nucleoside analogues are compounds which mimic the naturally occurring nucleosides sufficiently so that they are able to participate in viral DNA synthesis. However, the antiviral nucleoside analogues have strategically located differences in chemical structure which inhibit the viral enzyme reverse transcriptase or which prevent further DNA synthesis once the analogue has been attached to the growing DNA chain. Azidothymine (AZT), dideoxycytidine, dideoxyadenosine, acyclovir, ribavirin and vidarabine are examples of nucleoside analogues which have been under investigation or have been found effective in disrupting viral DNA or RNA synthesis (1).
Acquired immune deficiency syndrome (AIDS) has been referred to as the first great pandemic of the second half of the 20th century (2). AIDS is caused by the human immune deficiency virus (HIV). There is no effective cure for AIDS at the present time. Dideoxynucleoside analogues such as AZT are the most potent agents currently known, but in a recent human trial, serious toxicity was noted consisting of anemia (24%) and granulocytopenia (16%) (37, 38).
HIV infects cells bearing the CD4 (T4) surface antigen such as CD4 helper lymphocytes as well as CD4 monocytes and macrophages. The infection of C34 lymphocytes (3-5) results in a cytoiytic infection and contributes to the progressive immunodeficiency of HIV

infection (6, 7). More recently, CD4 monocyte/macrophages have been shown to be infected in vitro (8, 9), and in vivo (10-15). Infection of monocyte/macrophages may also contribute to immunodeficiency and to the pathogenesis of HIV induced encephalopathy. In addition, these cells may serve as a reservoir for the virus because HIV replication in monocyte/macrophages appears to be more prolonged and less cytolytic than in lymphocytes. (8, 9, 13). It would be desirable to provide a means for administering AZT and other dideoxynucleosides in a manner such that the toxic side effects of these drugs are reduced. Further, it would be desirable to provide selective targeting of the dideoxynucleoside to monocyte/macrophages to enhance the efficiency of the drug against viral infection in this group of cells.
In 1965 Alex Bangham and coworkers discovered that dried films of phosphatidylcholine spontaneously formed closed bimolecular leaflet vesicles upon hydration. They used these dispersions to study the capture and diffusion of cations (18). Eventually these structures came to be known as liposomes. Subsequently many potential uses for liposomes were suggested and by 1976 over 60 substances had been reported to become encapsulated in liposomes and a wide variety of uses for liposomes in medicine had been suggested including oral administration of liposomal insulin, selective targeting of liposomes to organs, replacement of missing enzymes and genetic material by liposomal carriers (19). Many of the above goals have proved elusive.
Selective targeting to most organs now seems virtually unattainable because of the tightness of the vascular system; only organs having sinusoids or fenestratsd endothelium seem to be possible targets (20, 21). Replacement of deficient enzymes or genetic material has also been difficult because of the relatively rapid

removal of liposomes from the vascular compartment and because fusion of liposomes with cell surface membranes seems not to occur readily (20).
As noted in a recent review by Marc Ostro there are many promising uses of liposomes which are nearing the clinical arena (22). For example, liposomal antimonial drugs are several hundred fold more effective than the free drug in treating leishmaniasis as shown independently by Black and Watson (23) and Alving et al (24). Liposome-entrapped amphotericin B appears to be more effective than the free drug in treating immunosuppressed patients with systemic fungal disease (25, 26). Other uses for liposome encapsulation include restriction of doxorubicin toxicity (27) and diminution of aminoglycoside toxicity (22).
As previously mentioned it is now thought that macrophages are an important reservoir of HIV infection
(28, 29 and 30) and that macrophages are also a primary site of liposome uptake (20, 21). Accordingly, it would be desirable to utilize liposomes to enhance the effectiveness of antiviral nucleoside analogues in treating AIDS.
Attempts have been made to incorporate nucleoside analogues, such as iododeoxyuridine (IUDR), acylovir (ACV) and ribavirin into liposomes for treating diseases other than AIDS (16, 17). However, these attempts have not been entirely satisfactory because these relatively small nucleoside analogues tend to rapidly leak out of the liposome (16, 17) resulting in decreased targeting effectiveness.
SUMMARY OF THE INVENTION
In accordance with the present invention a new treatment for AIDS is disclosed in which antiviral nucleoside analogues are trapped within liposomes in a manner which prevents or substantially reduces leakage.

This reduction in leakage provides reduced toxicity and the use of liposomes ensures that a greater amount of the antiviral nucleoside analogue reaches the macrophages to thereby increase the effectiveness of these drugs against the HIV infection present in such cells. The analogue of the neucleoside encapsulated in liposomes further enhances the antiviral effect of the formulation by providing a prephosphorylated antivral nucleoside, bypassing an enzymatically deficient step in macrophages which would otherwise greatly limit the antiviral activity of the drug itself (43).
The present invention is based on the discovery that leakage of nucleoside analogues from liposomes is greatly reduced if the analogues are converted to phosphate derivatives prior to encapsulation in liposomes. Conversion of the nucleoside analogues to their respective phosphate derivatives is believed not only to prevent leaking of the analogues from the liposomes, but also to increase the effectiveness of the analogues against HIV-infected macrophage cells. As previously mentioned, nucleosides are phosphorylated to the triphosphate form prior to attachment to the growing DNA or RNA chain. Macrophages have been found to have diminished deoxynucleoside kinase activities and a reduced ability to phosphorylate nucleosides. Accordingly, free nucleoside analogues (i.e., non-phosphorylated analogues), such as AZT, ddC or ddA are not particularly effective against HIV present in macrophage cells (43). However, the phosphorylated analogues of the present invention are more effective when presented by the lipsomal delivery system because they by-pass the metabolic block caused by the lack of deoxynucleoside kinase activity in macrophages.
The above-discussed features and attendant advantages of the present invention will become apparent as the invention becomes better understood by reference

to the following detailed descriptions.
DETAILED DESCRIPTION
The present invention basically involves the encapsulation of phosphorylated antiviral nucleoside analogues within liposomes for use in treating viral infections. Although this invention has applications to a wide variety of nucleoside analogues which may be used to treat various viral infections, the following description will be in the context of the treatment of patients suffering from Acquired Immune Deficiency
Syndrome (AIDS) and related retroviral infections such as AIDS-related complex (ARC), asymptomatic infections with HIV-1 and HIV-2 and malignant (lymphoma) or neurologic (tropical spastic paralysis) complications of
HTLV-1 or HTLV-2.
Human immunodeficiency virus (HIV, previously referred to as HTLV-III/LAV) is the etiologic agent of AIDS . As extrapolated from serological surveys, over 1,000,000 Americans have been infected since the virus was introduced into the United States in the late 1970’s. By now it is estimated that as many as two million people may be infected in the United States. Although the majority of these seropositive individuals are asymptomatic, most, if not all, remain persistently infected and thus constitute a pool of potential transmitters of infection. A significant fraction of these individuals have lymphadenopathy and other symptoms, and a smaller proportion, (a few percent per year) progress to AIDS with its grim prognosis. This minority now numbers over 35,000 in the United States alone and the number is doubling approximately yearly.
At a cellular level, HIV infects the CD4 (T4) helper lymphocyte resulting in the death of these cells. Depletion of CD4 helper lymphocytes makes the host vulnerable to certain well described opportunistic

infections and malignancies. HIV binds to the CD4 receptor of lymphocytes by forming a complex between the 110K viral surface glycoprotein (gp110) and the CD4 antigen (32, 32). Subsequently, the virus is thought to enter the cell by endocytosis as suggested by the finding that productive infection is blocked by NH4Cl and amantadine pretreatment of the cells. After presumed acid-mediated fusion with the endosome membrane the viral reverse transcriptase and RNA gain access to the cytoplasm and ultimately the viral genetic material gains access to the cell genome. As recently reviewed by Yarchoan and Broder (33) there are at least 9 steps in HIV replication which may provide targets fcr therapeutic intervention. At present, inhibition of viral reverse transcriptase represents the most promising avenue of antiretroviral therapy.
Recently it has been demonstrated that cells other than the CD4 helper lymphocyte become infected with HIV (28, 29, 30). The virus has been shown to replicate in B cells, promyelocytes and monocytes. It also has been shown that mononuclear phagocytes isolated from brain and lung harbored HIV and normal peripheral blood macrophages produced large quantities of virus. Furthermore, human alveolar macrophages and brain macrophages harbor HIV and the viral cytopathic effects on these cells are much less than that observed in HIV- infected helper T4 lymphocytes. It has been proposed that HIV-infected macrophages and monocytes may serve as a reservoir for virus and that this may be a mechanism for viral persistence and dissemination in the infected host (29, 30).
The present invention utilizes the affinity of macrophages for liposomes as a vehicle for directing liposome encapsulated antiviral nucleoside analogues at macrophages, monocytes and any other infected cells which may take up liposomes. Further, phosphorylation

of the nucleoside analogue prior to encapsulation provides advantages in that: 1) the nucleoside analogue is prevented from leaking out of the liposome; and 2) the metabolic block associated with the inability of macrophages to phosphorylate free nucleosides is overcome. Finally, liposomal encapsulation of the phosphorylated nucleoside is essential to prevent hydrolysis of the phosphate ester by plasma enzymes such as alkaline phosphatase, phosphodiesterases or 5′-nucleotidases.
The nucleoside analogues can be any of the known analogues used for treating AIDS including 3′-azido-3′-deoxythymidine (azidothymidine or AZT), 2 ‘, 3 ‘-dideoxycytidine (dideoxycytidine or ddC), 2’3′-dideoxyadenosine (dideoxyadenosine or ddA), ribavirin or any other suitable dideoxynucleoside analogue. AZT is a preferred analogue.
The analogue is phosphorylated according to conventional procedures such as the phosphorous oxychloride method of Toorchen and Topal (34). The preferred modified analogue is the 5′-monophosphate. Since AZT and other dideoxynucleosides have only the 5′-hydroxyl, only the 5′-monophosphate is formed during phosphorylation. Alternatively, the nucleoside 5′-monophosphate thioester is also effective. Diphosphate and triphosphate analogues of antiviral nucleosides are also effective, however, these diphosphate or triphosphate analogues tend to be less stable than the monophosphate and may be hydrolyzed gradually back to the monophosphate derivative in aqueous solution.
After phosphorylation, the nucleoside analogue is encapsulated in liposomes. The encapsulation can be carried out according to well known liposome encapsulation procedures such as sonication and extrusion. Suitable conventional methods of encapsulation include but are not limited to those disclosed by Bangham et al

(18), Olson et al (39), Szoka and Papahadjapoulos (40), Mayhew et al (41), Kim et al (42), Mayer et al (36) and Fukunaga et al (35).
The liposomes can be made from any of the conventional synthetic or natural phospholipid liposome materials including phospholipius from natural sources such as egg, plant or animal sources such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, sphingomyelin, phosphatidylserine or phosphatidylinositol. Synthetic phospholipids may also be used, such as, but not limited to, dimyristoylphosphatidylcholine, dioleoylphosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, dilauroylphosphatidylethanolamine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, dioleoylphosphatidylethanolamine and distearoylphosphatidylethanolamine. Other additives such as cholesterol or other sterols, glycolipids, cerebrosides, gangliosides, sphingolipids, glucopsychosine, or psychosine can also be added as is conventionally known. The relative amounts of phospholipid and additives used in the liposomes may be varied if desired. The preferred ranges are from about 80-99 mole percent phospholipid and 1 to 20 mole percent psychosine or other additive. Cholesterol may be used in amounts ranging from 0 to 50 mole percent. The relative amounts of antiviral nucleoside analogue entrapped in liposomes can be varied with the concentration of entrapped analogue in the liposome aqueous compartment ranging from about 0.001 mM to about 300 mM.
The liposome entrapped phosphorylated nucleoside analogue is administered to patients by any of the known procedures utilized for administering liposomes. The liposomes can be administered intravenously, intraperitoneally or intramuscularly as a buffered aqueous solution. Any pharmaceutically acceptable aqueous

buffer may be utilized so long as it does not destroy the liposome structure or the activity of the encapsulated phosphorylated nucleoside analogue. One suitable aqueous buffer is 150 mM NaCl containing 5mM Na-Phosphate with a pH of about 7.4; other physiological buffered salt solutions may also be used.
The dosage may vary depending upon the extent and severity of the infection. Dosage levels of encapsulated phosphorylated nucleoside analogue should be such that about 0.001 mg/kilogram to 1000 mg/kilogram be administered to the patient on a daily basis.
Examples demonstrating the reduction in leakage of phosphorylated nucleoside analogues from liposomes are as follows: Initial studies were carried out with. [3H]thymidine and [14C] thymidine-5′-monophosphate, 28.6×106DPM of [3H]thymidine and 2.5106DPM of [14C] thymidine-5′ -monophosphate [14C]TMP in 2.0 ml RPMI buffer was added to a thin film of egg phosphatidylcholine/cholestercl (molar ratio 2:1). After vortexing and swelling for 10 min the suspension was sonicated for 20 min and passed over a Sepharose 4B column as described by Fukunaga et al, (35). Table 1 shows the DPM (and %) of each compound entrapped in multilamellar (MLV) and small unilamellar vesicles (SUV). 1.1% of the [14C]TKP was retained in MLV versus only 0.1% of the [3H]thymidine. In SUV, 5% of the [14C]TMP was trapped versus only 0.4% of the [3H]thymidine.

When the above MLV and SUV were placed in an Amicon ultrafiltration cell and concentrated to a small volume, 86-87% of the [14C]TMP was retained by the liposomes versus only 18-21% for [3H]thymidine. Overall, only 0.02-.09% of the total [3H]thymidine was retained versus 0.9-4.3% retained for [14C]TMP. The fact that 50 times more [14C]TMP was ultimately retained in liposomes indicates that [3H] thymidine cannot be entrapped probably due to rapid diffusion across the lipid bilayer.
Labeled AZT-5′-monophosphate ([3H]AZT-MP) was prepared according to the phosphorous oxychloride method of Toorchen and Topal (34). Twenty nanomoles cf AZT (260 microcuries) was dried under nitrogen. Twenty microliters of trimethylphosphate and 4 microliters of triethylamine were added and the mixture cooled to -10°C. Four microliters of phosphorus oxychloride was added and the mixture was allowed to react at -10 °C for 30 minutes. The reaction was stopped by addition of an equal volume of 0.5 M aqueous triethylamine. AZT was converted to AZT-MP in a yield of greater than 90 percent as judged by HPLC on Altex C18 Ultrosphere-ODS column.
The resulting [3H]AZT-MP was encapsulated in liposomes in the same manner as the [14C]thymidine phosphate and then tested for leakage against free labeled AZT ([3H]AZT). The results of the tests are shown in Table 2. Only 0.2% of the [3H]AZT was entrapped in liposomes versus 3.8% of the [3H]AZT-KF. This indicates that [3H]AZT, like [3H]thymidine (Table 1), diffuses out of liposomes as they are being isolated on the Sepharose 4B column. In contrast, [3H]AZT-MP was entrapped readily; 3.8% of the total was recovered in the liposomal fraction, a 19 fold increase over the percent encapsulation of [3H]AZT.

The effect of liposomal AZT monophosphate on HIV replication in MT-2 and U937 cells and human macrophages in culture was tested as follows:
A thin film of 27 mg cholesterol and 110 mg egg phosphatidylcholine was prepared by rotary evaporation in vacuo and 1 ml of RPMI medium containing 60 nmol of AZT-MP and 6 uCi [3H]AZT-MP was added and the mixture was shaken at 20°C. for 20 min followed by 10 cycles of vortexing to produce MLV containing [3H]AZT-MP. Using a Lipex Extruder (Lipex Biomembranes, Inc.,
Vancouver, B.C.), small unilamellar vesicles of 100 nanometer diameter (EV 100) were prepared by the method of Mayer et al (36). This procedure is based on extrusion of large multilamellar vesicles through two stacked polycarbonate filters (Nucleopore, Pleasanton, CA).
The resulting liposome preparation was applied to a 1×15 cm column of Sepharose 4B and eluted with RPMI buffer. EV 100 liposomes containing [3H]AZT-MP eluted at the void volume while free [3H]-drug was collected in the column salt volume. Under these conditions, 14.3% of the [3H]AZT-MP was trapped. Higher encapsulation efficiencies can be obtained by using more phospholipid per unit volume of buffer and by repeated freezing and thawing (36).
EV 100 liposomes containing [3H]AZT-MP were added in various concentration to MT-2 and U937 cells growing in ELISA plates; to other wells were added AZT-MP and AZT. After 3 days the MT-2 cells (6×105 cells/well) were examined for cytopathic effects (CPE) and the results of CPE grading are shown in Table 3.

TABLE 3
Experiment E725
EFFECT OF LIPOSOMAL AZT-MP ON
HIV REPLICATION IN MT-2 CELLS. DAY 7
CPE rmol Free AZT-MP AZT-MP drug/well AZT Liposome A Liposome B
2 0;0 0;0 0;0
0.2 0;0 0;0 0;0
0.02 4+4+ 3+;0 0;0
0.002 4+;4 4+;4+ 0;0
0.002 4+;4+ 4; 4+ 4+;4+
Control, no drug, 4+4+; CPE, cytopathic effects. Liposomes containing [3H]AZT-monophosphate were prepared in RPMI medium by the method of Mayer et al (36) and the liposomal AZT-MP encapsulated was determined by the 3H content of the pooled liposomal peak. Liposomes containing [3H] -AZT-MP were added to MT-2 cells infected with HIV in a final volume of 0.200 ml of RPMI medium containing 10% fetal calf serum. Liposome A consisted of 67 mole % egg phosphatidylcholine and 33 mole % cholesterol and Liposome B was made up of 6.6 mole % psychosine and 60 mole % egg phosphatidylcholine and 33.3 mole % cholesterol. Grading of CPD was done as described by Haertle et al (44). In this system 1+ corresponds to 1 to 3 syncytia (giant cells) per well. 2+ corresponds to 3-10 syncytia per well and up to 20% cell death; 3+ corresponds to 10-30 syncytia per well

and 20-70% drop in cell viability; 4+ corresponds to more than 30 syncytia per well and at least a 70% fall in viable cell count (44).
Similarly, 6×105 U937 cells growing in ELISA plates were inoculated with HIV. AZT, AZT-MP and liposomal AZT-MP were added to the culture medium as noted above. After 4 days of growth the cell supernatants were removed, diluted 1:100 and assayed for HIV gp24 using the Dupont ELISA System (NEK-041). The results are shown in Table 4.
TABLE 4 EFFECT OF LIPOSOMAL AZT-MP ON HIV REPLICATION IN U937 CELLS qp24 Antigen , pg /ml
umol nmol AZT-MP AZT-MP lipid/well drug/well Free AZT Liposome A Liposome B
2.72 2.0 1050 30 30
0.86 0.63 1200 30 30
0.27 0.20 3450 30 30
0.086 0.063 2850 30 30
0.027 0.020 3500 850 30
0.0086 0.0063 2800 2,100 1,600
Liposomes containing [3H]AZT-MP were prepared as in Table 1 and added to U937 cells infected with HIV in 0.200 ml of RPMI containing 10% fetal calf serum. Liposome A consisted of 67 mole % egg phosphatidylcholine and 33 mole % cholesterol and liposome B contained 6.6 mole % psychosine and 60 mole % egg

phosphatidylcholine and 33 mole % cholesterol. Results are mean of 2 replicates.
The effect of liposomal AZT-monophosphate on cultured human macrophages was also determined following the procedures used for MT-2 cells and U937 cells. The results are set forth in Table 5.
TABLE 5
EFFECT OF LIPOSOMAL AZT-MP ON HIV REPLICATION IN CULTURED HUMAN MACROPHAGES qp24 Antigen, pg/ml
umol nmol AZT-MP AZT-MP lipid/well drug/well Free AZT Liposome A Liposome B
– 20.0 2016 n.d. n.d.
– 6.3 1844 n.d. n.d.
2.72 2.0 2524 30 30
0.86 0.63 2480 30 30
0.27 0.20 2116 30 160
0.086 0.063 2172 30 30
0.027 0.020 n.d. 30 220
0.0086 0.006 n.d. 300 648
n.d. = not determined. Liposome of egg phosphatidylcholine containing [3H]AZT-MP in the indicated concentration were prepared as in Tab^e 1 and added to human macrophages. After 3 days in culture the supernatants were assayed for gp24. Liposome A consisted of 67 mole % egg phosphatidylcholine and 33 mole % cholesterol and liposome B contained 6.6 mole % psychosine and 60 mole % egg phosphatidylcholine and 33 mole % cholesterol. Additional examples of practice are as follows:
Liposomes of egg phosphatidylcholine/cholesterol (2/1) (100 nanometer diameter) containing [3H]AZT-MP were prepared in RPMI medium by the extrusion method of

Mayer et al (36), and the amount of [3H]AZT-MP encapsulated was determined by 3H counts in the voiding peak obtained by gel permeating chromatography using Sepharose 4B. Varying amounts of AZT-MP were added and the effect determined on cells infected with HIV by measuring production of HIV antigen gp24 using the DuPont Elisa assay kit. Two liposome types were prepared — liposome A and liposome B. Liposome A consisted of 67 mole % egg phosphatidylcholine and 33 mole % cholesterol and liposome B contained 6.6 mole % psychosine and 60 mole % egg phosphatidylcholine and 33 mole % cholesterol. The results of the tests are shown in Table 6.
TABLE 6
EFFECT OF LIPOSOMAL AZT-MP ON HIV REPLICATION IN U937 CELLS
gp24 Antigen, pg/ml
umol nmol AZT-MP AZT-MP
PC/well drug/well Free AZT Liposome A Liposome B
4.6 2.0 2,740 60 60
0.46 0.2 3,120 78 60
0.046 0.02 5,060 2,140 1,353
0.0046 0.002 4,460 2,120 13,290
0.00046 0.0002 10,910 13,100 13,980
0 0 (15,420) –
The liposomal AZT-MP prepared for testing against
U937 cells as set forth in Table 6 was also used against
HIV-infected human macrophages. The tests were conducted in the same manner as previously described for
Table 6 and the results are set forth in Table 7.

TABLE 7
EFFECT OF LIPOSOMAL AZT-MP ON
HIV REPLICATION IN HUMAN MACROPHAGES
qp24 Antigen, pg/ml
umol nmol AZT-MP AZT-MP
PC/well drug/well Free AZT Liposome A Liposome B
4.6 2.0 2,016 30 30
0.46 0.2 1,872 30 30
0.046 0.02 2,268 30 49
0.0046 0.002 2,132 2,084 1, 632
0.00046 0.0002 2,248 1,732 1,316
0.000046 0.00002 2,800 1,448 1,744
0 0 2,276 –
Having thus described exemplary embodiments of the present invention, it should be noted by those skilled in the art that the within disclosures are exemplary only and that various other alternatives, adaptations and modifications may be made within the scope of the present invention. Accordingly, the present invention is not limited to the specific embodiments as illustrated herein, but is limited only by the following claims.

BIBLIOGRAPHY
Hirsch, M.S., J.C. Kaplan. 1987. Antiviral
Therapy. Scientific American (April 1987) pages
76-85.
Gallo, R.C. 1987. The AIDS Virus. Scientific
American (January 1987) pages 47-56.
Dalgleish, A.G., P.C.L. Beverley, P.R. Claphan,
D.H. Crawford, M.F. Greaves, and R.A. Weiss. 1984.
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature
312:763.
Klatzman, D., E. Champagne, S. Chamaaret, J.
Gruest, D. Guetard, T. Hercend, J.-C. Gluckman, and
L. Montagnier. 1984. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.
Nature 312:767.
Maddon, P. J., A.G. Dalgleish, J.S. McDouglal, P.R. Clapham, R.A. Weiss, and R. Axel. 1986. The T4 gene enclodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47:333.
Lifson, J.D., M.B. Feinberg, G.R. Reyes, L. Rabin, B. Banapour, S. Chakrabarti, B. Moss, F. WongStaal, K.S. Steimer, and E.G. Engleman. 1986. Induction of CD4-dependent cell fusion by the HTLV- 111/LAV envelope glycoprotein. Nature 323:725. Yoffe, B., D. Lewis, B. Petrie, C. Noonan, J. Melnick, F.B. Hollinger. 1987. Fusion as a meadiator of cytolysis in mixtures of uninfected CD4+ lymphocytes and cells infected by human immunodeficiency virus. Proc. Natl. Acad. Sci. 84:1429.
Ho, D.D., T.R. Rota, and M.S, Hirsch. 1986
Infection of monocyte/nacrophages by human T lymphotropic virus type III. J. Clin. Invest. 77:1712.

9. Chayt, K.S., M.E. Harper, L.M. Marselle, E.B. Lewin, R.M. Rose, J.M. Oleske, L.G. Epstein, F. Wong-Staal, and R.C. Gallo. 1986. Detection of HTLV-III RNA in lungs of patients with AIDS and pulmonary involvement. JAMA 256:2356.
10. Tschachler, E., V. Groh, M. Popovic, D.L. Mann, K. Konrad, B. Safai, L. Eron, F. diMarzo Veronese, K. Wolff and G. Stingl. 1987. Epidermal Langerhans cells – a target for HTLV-III/LAV infection. J. Invest. Dermatol. 88:233.
11. Mitsuya, H., K.J. Wemhold, P.A. Furman, M.H. St. Clair, S. Nusinoff Lehrman, R.C. Gallo, D. Bolognesi, D.W. Barry and S. Broder. 1985. 3′- azido-3′-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type Ill/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. 82:7096.
12. Mitsuya, H. and S. Broder. 1986. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadeno- pathy-associated virus (HTLV-III/LAV) by 2′,3′- dideoxynucleosides. Proc. Natl. Acad. Sci. 83:1911. 13. Furman, P.A., J.A. Fyfe, M.H. St. Clair, K. Weinhold, J.L. Ridcout, G.A. Freeman, S. Nusinoff Lehrman, D.P. Bolognesi, S. Broder, H. Mitsuya, and D.W. Barry. 1986. Phosphorylation of 3′-azido-3′- deoxythymidine and selective interaction of the 5′- triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci.
83:8333.
14. Cooney, D.A., M. Dalai, H. Mitsuya, J.B. McMahon,
M. Nadkarni, J. Balzarini, S. Broder, and D.G. Johns. 1986. Initial studies on the cellular pharmacology of 2′, 3′-dideoxycytidine, an inhibitor

of HTLV-III infectivity. Biochem. Pharmacol.
35:2065.
15. Yarchoan, R.Y., R.W. Klecker, K.J. Weinhold, P.D. Markham, H.K. Lyerly, D.T. Durack, E. Gelmann, S. Nusinoff Lehrman, R.M. Blum, D.W. Barry, G.M.
Shearer, M.A. Fischl, H. Mitsuya, R.C. Gallo, J.M. Collins, D.P. Bolognesi, C.E. Myers, S. Broder. 1986. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet
8481:575.
16. Norley, S.G., L. Huang and B.T. Rouse, 1987. Targeting of Drug Loaded Immunoliposomes to Herpes Simplex Virus Infected Corneal Cells: An Effective Means of Inhibiting Virus Replication in Vitro.
Journal of Immunology. Vol. 136, No. 2: 681-685.
17. Kond, M., Alving, C.R., Rill, W.L., Swartz, G.M. and Cannonico, PP.G. 1985. Enhanced Efficacy of Liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice. Antimicrob Agents
Chemother. 27: 903-907.
18. Bangham, A.D., Standish, M.M. and Watkins, J.C. (1965) J. Mol. Biol., 13:238-252.
IS. Gregoriadis, G. (1976) New Eng. J. Med., 295:704710 and 765-770.
20. Post, G., Kirsch, R. and Koestler, T. (1984) in Liposome Technology, Vol. Ill, G. Gregoriadis, Ed., CRC Press, Boca Raton, p.1-28.
21. Scherphof, G. (1986) in Lipids and Membranes, Past, Present and Future, Op den Kamp J., Roelofsen, B. and Wirtz, K.W.A., eds., Elsevier North Holland, Amsterdam, p 113-136.
22. Ostro, M. (1987) Sci. Am. 256:103-111.
23. Black, C.D.V., Watson, G.J. and Ward, R.J. (1977, Trans. Roy. Soc. Trop. Med. Hyg. 71:550-552
24. Alving, C.R., Steck, E.A. , Chapman, W.L. Waits,

V.B., Hendricks, L.D., Swartz, G.M. , Hanson, W.L. (1978) Proc. Natl. Acad. Sci. USA, 75:2959-2963. 25. Lopez-Berestein, G. (1986) Ann. Int. Med., 105:130- 131. 26. Shirkhoda, A., Lopez-Berestein, G., Holbert, J.M. and Luna, M.A. (1986) Radiol., 159:349-353.
27. Herman, E.H., Rahman, A. Ferrans, V. J., Vick, J.A., and Schein, P.S. (1983) Cancer Res., 43:5427-5432.
28. Levy, J., et al. (1985) Ann. Int. Med. 103:694-699. 29. Salahuddin, S.Z., Rose, R.M. , Groopman, J.E.,
Markham, P.D., and Gallo R.C. (1985) Blood 68:281- 284.
30. Koenig, S., Gendelman, H.E., Orenstein, J.M., Dalcanto, M.C., Pezeshkpur, G.H., Yungbluth, M., Janotta, F., Aksmit, A., Martin, M.A. and Fauci,
A.S. (1986) Science, 233: 1089-1093.
31. McDougal, J.S., Kennedy, M.S., Sligh, J.M., Cort, S.P., Mawle, A. and Nicholson, J.K.A. (1986) Science 231:382-385. 32. Kaddon, P.J. Dalgleish, A.G., McDouglas, J.S. Clapham, P.R., Weiss, R.A. and Axel, R. (1986) Cell 47:333-348.
33. Yarchoan, R. , Weinhold, K.J. Lyerly, H.K. Gelraan, E., Blum, R.M., Shearer, G.M., Mitsuya, H., Collins, J.M., Myers, C.E., Klecker, R.W., Markham,
P.D., Durack, D.T., Lehrman, S.N., Barry, D.W., Fischl, M.A., Bolognesi, D.P., and Broder, S.
(1986) Lancet, March 15, 575-580.
34. Toorchen, D. and Topal, M.D. (1983) Carcinogenesis 4:1591-1597.
35. Fukunaga, M., Miller, M.M., Hostetler, K.Y. and Deftos, L.J. (1984) Endocrinol. 115:757-761.
36. Mayer, L.D., Hope, M.J. and Cullis, P.R. (1986) Biochim. Biophys. Acta. 858:161-168. 37. Fischl, M.A., Richman, D.D., Grieco, M.H., et al,
(1987) New Eng. J. Med., 317:185-191.

38. Richman, D.D., Fischl, M.A., Grieco, M.H., et al, (1987), New Eng. J. Med., 317:192-197.
39. Olson, F., Hunt, CA., Szoka, F.C., Vail, W.J. and Papahadj opoulos, D. (1979) Biochim. Biophys. Acta. 557:9-23.
40. Szoka, F., Jr. and Papahadjopoulos, D. (1978) Proc. Nat. Acad. Sci. 75:4194-4198.
41. Mayhew, E., Lazo, R., Vail, W.J., King, J., Green, A.M. (1984) Biochim. Biophys. Acta 775:169-175. 42. Kim, S., Turker, M., Chi, E., et al (1978) Biochim. Biophys. Acta. 728:339-348.
43. Richman, D.D., Kornbluth, R.S. and Carson, D.A. (1987) J. Exp. Med., 166:1144-1149.
44. Haertle, T., Carrera, C.J., McDougal, J.S., Sowers, L.C., Richman, D.D. and Carson D.A. (1987) J. Biol.
Chem., in press.

Claims (31)

What is claimed is:

1. A composition for use in treating acquired immune deficiency syndrome and related retroviral infections comprising a phosphorylated nucleoside analogue which is encapsulated in a liposome and a pharmaceutically acceptable carrier therefor.

2. A composition according to claim 1 wherein said nucleoside analogue is selected from the group consisting of azidothymidine, dideoxycytidine, dideoxyadenosine and ribavirin.

3. A composition according to claim 2 wherein said phosphorylated nucleoside analogue is the 5′-monophosphate derivative of azidothymidine.

4. A composition according to claim 2 wherein said phosphorylated nucleoside analogue is the 5′-monophosphate derivative of dideoxyadenosine.

5. A composition according to claim 2 wherein said phosphorylated nucleoside analogue is the 5′-monophosphate derivative of dideoxycytidine.

6. A composition according to claim 2 wherein said phosphorylated nucleoside analogue is the 5′-monophosphate derivative of ribavirin.

7. A composition according to claim 1, wherein said liposome is made from at least one of the phospholipids selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, sphingomyelin, phosphatidylserine, phosphatidylinositol, dilauroylphosphatidylcholine, dimyristoylphosphatidylcholine, dioleoylphosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, dilauroylphosphatidylethanolamine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, dioleoylphosphatidylethanolamine and distearoylphosphatidylethanolamine.

8. A composition according to claim 7 wherein said liposome further includes additives selected from the group consisting of cholesterol, glycolipids, cerebrosides, gangliosides, sphingolipids, glucopsychosine, and psychosine.

9. A composition according to claim 8 wherein said liposome consists essentially of from about 80-99 mole percent egg phosphatidylcholine and from about 1 to 20 mole percent psychosine.

10. A composition according to claim 9 wherein said phosphorylated nucleoside analogue is the 5′-monophosphate derivative of azidothymidine.

11. A composition according to claim 1 wherein said pharmaceutically acceptable carrier is an aqueous buffer.

12. A method for treating acquired immune deficiency syndrome and related retroviral infections in mammals comprising the step of administering to said mammal a pharmaceutically acceptable dose of a composition comprising a phosphorylated nucleoside analogue which is encapsulated in a liposome and a pharmaceutically acceptable carrier therefor.

13. A method according to claim 12 wherein said nucleoside analogue is selected from the group consisting of azidothymidine, dideoxycytidine, dideoxyadenosine and ribavirin.

14. A method according to claim 13 wherein said phosphorylated nucleoside analogue is the 5′-monophosphate derivative of azidothymidine.

15. A method according to claim 13 wherein said phosphorylated nucleoside analogue is the 5′-monophosphate derivative of dideoxyadenosine.

16. A method according to claim 13 wherein said phosphorylated nucleoside analogue is the 5’ derivative of dideoxycytidine.

17. A method according to claim 13 wherein said phosphorylated nucleoside analogue is the 5 ‘-monophosphate derivative of ribavirin.

18. A method according to claim 12 wherein said liposome is made from phospholipids selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, sphingomyelin, phosphatidylserine, phosphatidylinositol, dilauroylphosphatidylcholine, dimyristoylphosphatidylcholine, dioleoylphosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, dilauroylphosphatidylethanolamine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, dioleoylphosphatidylethanolamine and distearoylphosphatidylethanolamine.

19. A method according to claim 18 wherein said liposome further includes an additives selected from the group consisting of cholesterol, glycolipids, cerebrcsides, gangliosides, sphingolipids, glucopsychosine, and psychosine.

20. A method according to claim 19 wherein said liposome consists essentially of from about 80-99 mole percent egg phosphatidylcholine and from about 1 to 20 mole percent psychosine.

21. A method according to claim 20 wherein said phosphorylated nucleoside analogue is the 5′-monophosphate derivative of azidothymidine.

22. A method according to claim 12 wherein said pharmaceutically acceptable carrier is an aqueous buffer.

23. A method according to claim 12 wherein said composition is administered intravenously to said mammal.

24. A composition according to claim 7 wherein the concentration of the phosphorylated nucleoside analogue entrapped within said liposome is between about 0.001 ml-l to 300 mM.

25. A method for preparing a medicament comprising the steps of encapsulating a phosphorylated nucleoside analogue in a liposome to form an encapsulated phosphorylated nucleoside analogue and combining said encapsulated phosphorylated nucleoside analogue with a pharmaceutically acceptable carrier therefor.

26. A method for preparing a medicament according to claim 25 wherein said phosphorylated nucleoside analogue is selected from the group consistmg of azidothymidine, dideoxycytidine, dideoxyadenosine and ribavirin.

27. A method for preparing a medicament according to claim 25 wherein said phosphorylated nucleoside analogue is prepared by reacting a nucleoside analogue with phosphorous oxychloride in the presence of trimethylphosphate and triethylamine.

28. A method for preparing a medicament according to claim 26 wherein said phosphorylated nucleoside analogue is the 5′-monophosphate derivative of azidothymidine.

29. A method for preparing a medicament according to claim 25 wherein said liposome is made from a phospholipid selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, sphingomyelin, phosphatidylserine, phosphatidylinositol, dilauroylphosphatidylcholine, dimyristoylphosphatidylcholine, dioleoylphosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, dilauroylphosphatidylethanolamine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, dioleoylphosphatidylethanolamine and distearoylphosphatidylethanolamine.

30. A composition according to claim 1 wherein said nucleoside analogue is a diphosphate derivative.

31. A composition according to claim 1 wherein said nucleoside analogue is a triphosphate derivative.

AU25261/88A
1987-09-22
1988-09-19
Liposomal nucleoside analogues for treating aids

Abandoned

AU2526188A
(en)

Applications Claiming Priority (2)

Application Number
Priority Date
Filing Date
Title

US9975587A

1987-09-22
1987-09-22

US099755

1987-09-22

Publications (1)

Publication Number
Publication Date

AU2526188A
true

AU2526188A
(en)

1989-04-18

Family
ID=22276457
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU25261/88A
Abandoned

AU2526188A
(en)

1987-09-22
1988-09-19
Liposomal nucleoside analogues for treating aids

Country Status (4)

Country
Link

EP
(1)

EP0380558A4
(en)

JP
(1)

JPH03501253A
(en)

AU
(1)

AU2526188A
(en)

WO
(1)

WO1989002733A1
(en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US6448392B1
(en)

1985-03-06
2002-09-10
Chimerix, Inc.
Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use

US5223263A
(en)

1988-07-07
1993-06-29
Vical, Inc.
Liponucleotide-containing liposomes

US5817638A
(en)

1988-07-07
1998-10-06
Nexstar Pharmaceuticals, Inc.
Antiviral liponucleosides: treatment of hepatitis B

US6252060B1
(en)

1988-07-07
2001-06-26
Nexstar Pharmaceuticals, Inc.
Antiviral liponucleosides: treatment of hepatitis B

US6599887B2
(en)

1988-07-07
2003-07-29
Chimerix, Inc.
Methods of treating viral infections using antiviral liponucleotides

ZA902710B
(en)

1989-05-22
1991-12-24
Univ Georgia Res Found
Enzyme luminescence assay

DE3916595A1
(en)

1989-05-22
1990-11-29
Boehringer Mannheim Gmbh

METHOD FOR NON-RADIOACTIVE MEASURING OF NUCLEIC ACID SYNTHESIS IN EUKARYONTIC CELLS

US5194654A
(en)

1989-11-22
1993-03-16
Vical, Inc.
Lipid derivatives of phosphonoacids for liposomal incorporation and method of use

US5463092A
(en)

1989-11-22
1995-10-31
Vestar, Inc.
Lipid derivatives of phosphonacids for liposomal incorporation and method of use

EP0461225B1
(en)

1989-12-08
1998-03-18
City Of Hope
Circumvention of human tumor drug resistance

FR2683721B1
(en)

1991-11-15
1995-06-09
Inocosm Laboratoires

POLAR LIPID COMPOSITION FOR VEHICULATING AN ACTIVE AGENT AND / OR PENETRATING IT INTO A TARGET CELL.

US5817646A
(en)

1991-11-15
1998-10-06
Laboratoires Inocosm
Polar lipid composition of plant origin

US20020120130A1
(en)

1993-09-10
2002-08-29
Gilles Gosselin
2′ or 3′ -deoxy and 2′, 3′ -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents

DE69636734T2
(en)

1995-06-07
2007-10-18
Emory University

NUCLEOSIDE WITH ANTI-HEPATITIS B VIRUS EFFICACY

US5795909A
(en)

1996-05-22
1998-08-18
Neuromedica, Inc.
DHA-pharmaceutical agent conjugates of taxanes

EP2390257A1
(en)

1998-02-25
2011-11-30
Emory University
2′-fluoronucleosides

ATE313550T1
(en)

1998-08-10
2006-01-15
Idenix Cayman Ltd

BETA-L-2′-DEOXYNUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B VIRUS

US6444652B1
(en)

1998-08-10
2002-09-03
Novirio Pharmaceuticals Limited
β-L-2’-deoxy-nucleosides for the treatment of hepatitis B

ATE408410T1
(en)

1998-11-02
2008-10-15
Gilead Sciences Inc

COMBINATION THERAPY FOR THE TREATMENT OF HEPATITIS B INFECTIONS

CA2380924C
(en)

1999-08-13
2008-02-19
University Of Maryland Biotechnology Institute
Compositions for treating viral infections, and methods therefor

DE60123042T2
(en)

2000-03-29
2007-04-12
Georgetown University

L-FMAU FOR THE TREATMENT OF HEPATITIS DELTA VIRUS INFICATION

US6761901B1
(en)

2000-05-02
2004-07-13
Enzrel Inc.
Liposome drug delivery

MY164523A
(en)

2000-05-23
2017-12-29
Univ Degli Studi Cagliari
Methods and compositions for treating hepatitis c virus

AP1727A
(en)

2000-05-26
2007-03-06
Idenix Cayman Ltd
Methods and compositions for treating flaviviruses and pestiviruses.

US6787526B1
(en)

2000-05-26
2004-09-07
Idenix Pharmaceuticals, Inc.
Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides

US6875751B2
(en)

2000-06-15
2005-04-05
Idenix Pharmaceuticals, Inc.
3′-prodrugs of 2′-deoxy-β-L-nucleosides

US6689760B1
(en)

2000-07-10
2004-02-10
Enzrel Inc.
Anti-mycobacterial compositions

US6455073B1
(en)

2000-07-10
2002-09-24
Enzrel, Inc.
Covalent microparticle-drug conjugates for biological targeting

DE60143672D1
(en)

2000-10-18
2011-01-27
Pharmasset Inc

MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRUS INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION

CN1503796B
(en)

2001-03-01
2012-07-04
三角药品公司
Polymorphic and other crystalling forms of cis-ftc

JP2005504087A
(en)

2001-09-28
2005-02-10
イデニクス（ケイマン）リミテツド

Methods and compositions for the treatment of hepatitis C virus using 4 ‘modified nucleosides

EP1474108A2
(en)

2002-01-09
2004-11-10
Enzrel, Inc.
Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds

AU2003247084B9
(en)

2002-06-28
2018-07-26
Centre National De La Recherche Scientifique
Modified 2′ and 3′-nucleoside prodrugs for treating flaviridae infections

EP1536804A4
(en)

2002-06-28
2007-10-31
Idenix Cayman Ltd
2′-c-methyl-3′-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections

US7608600B2
(en)

2002-06-28
2009-10-27
Idenix Pharmaceuticals, Inc.
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections

TWI244393B
(en)

2002-08-06
2005-12-01
Idenix Pharmaceuticals Inc
Crystalline and amorphous forms of beta-L-2′-deoxythymidine

PT1572095E
(en)

2002-09-13
2015-10-13
Novartis Ag
Beta-l-2′-deoxynucleosides for use in the treatment of resistant hbv strains

BR0316363A
(en)

2002-11-15
2005-10-04
Idenix Cayman Ltd

2′-branched nucleosides and flaviviridae mutation

PL2604620T3
(en)

2003-05-30
2016-12-30

Modified fluorinated nucleoside analogues

PL1658302T3
(en)

2003-07-25
2011-03-31
Idenix Pharmaceuticals Inc
Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c

AU2005228410A1
(en)

2004-03-29
2005-10-13
University Of South Florida
Effective treatment of tumors and cancer with triciribine and related compounds

US8492539B2
(en)

2004-09-14
2013-07-23
Gilead Pharmasset Llc
Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives

EP3159351A3
(en)

2005-09-26
2017-05-17
Gilead Pharmasset LLC
Modified 3′-azido-4′-ethynyl-nucleosides as antiviral agents

US8895531B2
(en)

2006-03-23
2014-11-25
Rfs Pharma Llc
2′-fluoronucleoside phosphonates as antiviral agents

US7964580B2
(en)

2007-03-30
2011-06-21
Pharmasset, Inc.
Nucleoside phosphoramidate prodrugs

EP3042660A3
(en)

2008-04-15
2016-10-26
RFS Pharma, LLC.
Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections

BRPI0923815A2
(en)

2008-12-23
2015-07-14
Pharmasset Inc

Purine nucleoside synthesis

PA8855701A1
(en)

2008-12-23
2010-07-27

NUCLEOSID ANALOGS

SG172359A1
(en)

2008-12-23
2011-07-28
Pharmasset Inc
Nucleoside phosphoramidates

US8618076B2
(en)

2009-05-20
2013-12-31
Gilead Pharmasset Llc
Nucleoside phosphoramidates

TWI598358B
(en)

2009-05-20
2017-09-11
基利法瑪席特有限責任公司
Nucleoside phosphoramidates

RS54368B1
(en)

2010-03-31
2016-04-28
Gilead Pharmasset Llc
Crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1-(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate

AU2011336632B2
(en)

2010-11-30
2015-09-03
Gilead Pharmasset Llc
Compounds

US8889159B2
(en)

2011-11-29
2014-11-18
Gilead Pharmasset Llc
Compositions and methods for treating hepatitis C virus

US9089574B2
(en)

2011-11-30
2015-07-28
Emory University
Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections

EA201690473A1
(en)

2013-08-27
2017-03-31
ГАЙЛИД ФАРМАССЕТ ЭлЭлСи

COMBINED COMPOSITION OF TWO ANTI-VIRUS COMPOUNDS

Family Cites Families (11)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US4235871A
(en)

1978-02-24
1980-11-25
Papahadjopoulos Demetrios P
Method of encapsulating biologically active materials in lipid vesicles

US4291024A
(en)

1978-04-10
1981-09-22
Turcotte Joseph G
Cytotoxic liponucleotide analogs

ZA833446B
(en)

1982-05-28
1984-02-29
Solco Basel Ag
Process for the preparation of cell-and tissue-regenerating substances

EP0114577A1
(en)

1983-01-21
1984-08-01
MAGIS FARMACEUTICI S.p.A.
New pharmaceutical composition

EP0152379A3
(en)

1984-02-15
1986-10-29
Ciba-Geigy Ag
Process for preparing pharmaceutical compositions containing unilamellar liposomes

WO1987001283A1
(en)

1985-08-26
1987-03-12
United States Of America, Represented By The Unite
Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2′,3′-dideoxycytidine

US4704357A
(en)

1985-09-30
1987-11-03
United States Of America As Represented By The Department Of Health And Human Services
Immortalized T-lymphocyte cell line for testing HTLV-III inactivation

US4916122A
(en)

1987-01-28
1990-04-10
University Of Georgia Research Foundation, Inc.
3′-Azido-2′,3′-dideoxyuridine anti-retroviral composition

IE63869B1
(en)

1986-11-06
1995-06-14
Res Dev Foundation
Aerosols containing liposomes and method for their preparation

NL8700089A
(en)

1987-01-15
1988-08-01
Stichting Rega V Z W
Medicaments for treating AIDS – contg. 2′,3′-di:deoxy-thymidine or 2′,3′-di:deoxy-thymidinene

IL86009A
(en)

1987-04-10
1991-09-16
Us Health
Liposome-encapsulated phosphorylated nucleosides for treatment of retroviral diseases

1988

1988-09-19
WO
PCT/US1988/003210
patent/WO1989002733A1/en
not_active
Application Discontinuation

1988-09-19
JP
JP63508005A
patent/JPH03501253A/en
active
Pending

1988-09-19
AU
AU25261/88A
patent/AU2526188A/en
not_active
Abandoned

1988-09-19
EP
EP19880908811
patent/EP0380558A4/en
not_active
Ceased

Also Published As

Publication number
Publication date

WO1989002733A1
(en)

1989-04-06

JPH03501253A
(en)

1991-03-22

EP0380558A1
(en)

1990-08-08

EP0380558A4
(en)

1991-07-31

Información de contacto